FDA issues statement reaffirming positive benefit-risk profile of NUPLAZID® (pimavanserin)
ACADIA Pharma announced the FDA has completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of NUPLAZID (pimavanserin) for patients with Parkinson’s disease psychosis. NUPLAZID is the only medicine approved in the U.S. September 20, 2018